EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Multidimensional Assessment of Neurological Adverse Reactions Related to PD ‐1 Inhibitors: A Real‐World Pharmacovigilance Study

Xiaofeng Hu, Xiaoli Wang, Bufu Tang iD, Dehuan Zhang, Rongbing Cai, Hui Jiang, Yaling Lin, Yiheng Song, Yiou Wang, Hairuo Huang, Dandan Guo iD, Xubin Sun und 1 weitere

CNS Neuroscience & Therapeutics · 2026

DOI: 10.1002/cns.70734 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2026. Verfasst von Xiaofeng Hu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Guangyuan Central Hospital, Guangyuan, Sichuan, China. Hauptthemen laut MEDLINE: Pharmacovigilance, Immune Checkpoint Inhibitors, Programmed Cell Death 1 Receptor, Nervous System Diseases. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

PD‐1 inhibitors have revolutionized cancer immunotherapy but present significant neurological safety concerns. While clinical trials have documented neurological adverse events (nAEs), a comprehensive understanding of their patterns and risk factors remains limited. This study systematically analyzed a decade of FAERS data to investigate PD‐1 inhibitor–associated neurotoxicities.

Methods

Using FAERS data (2014–2024), we conducted disproportionality analyses (ROR, IC, PRR) to assess PD‐1 inhibitor–nAE associations. Risk factors were evaluated using logistic regression; timing analyses used log‐rank and Mann–Whitney U tests, while group comparisons used Chi‐square tests.

Results

Among 115,000 PD‐1 inhibitor–associated adverse events, 7968 (6.93%) involved nAEs, showing an increasing trend from 4.96% (Q4 2014) to 7.67% (Q1‐Q2 2024). PD‐1 inhibitors showed significant nAE signals (ROR: 1.21, 95% CI: 1.18–1.23), with cemiplimab showing the strongest association (ROR: 1.38, 95% CI: 1.18–1.62). The most common nAEs were dizziness ( N = 942, 10.3%), encephalitis ( N = 435, 4.8%), and cerebrovascular accident ( N = 451, 4.9%). Risk factors included age > 65 years (OR: 1.10), female sex (OR: 1.04), skin cancer (OR: 1.36), and nervous system cancers (OR: 1.44). The median onset time was 34 days (IQR: 12–104), with 63.8% occurring within 2 months and 59% resulting in severe outcomes.

Conclusion

This study reveals a spectrum of PD‐1 inhibitor–related neurological toxicities, mainly involving central nervous system dysfunction, providing important insights into risk patterns and timing characteristics. These findings support improved clinical monitoring practices and inform the development of personalized patient care strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PharmacovigilanceImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorNervous System DiseasesNeurotoxicity SyndromesHumansMaleFemaleAgedMiddle AgedAdultAged, 80 and overRisk FactorsYoung Adult

Stichwörter der Autor:innen

FAERSPD‐1 inhibitoradverse eventsimmunotherapyneurological adverse eventspharmacovigilance

Substanzen

Immune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorPDCD1 protein, human

Autor:innen und Institutionen

  • Department of Oncology, Guangyuan Central Hospital, Guangyuan, Sichuan, China.
  • Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P.R. China.
  • Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Dalian Medical University, Dalian, P.R. China.
  • The Fourth Clinical College of China Medical University, Shenyang, China.
  • Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

ORCID-Profile: Bufu Tang, Dandan Guo, Hongjie Fan

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Hu, X., Wang, X., Tang, B., Zhang, D., Cai, R., Jiang, H., Lin, Y., Song, Y., Wang, Y., Huang, H., Guo, D., Sun, X., & Fan, H. (2026). Multidimensional Assessment of Neurological Adverse Reactions Related to PD ‐1 Inhibitors: A Real‐World Pharmacovigilance Study. CNS Neuroscience & Therapeutics. https://doi.org/10.1002/cns.70734

Vancouver

Hu X, Wang X, Tang B, Zhang D, Cai R, Jiang H, et al. Multidimensional Assessment of Neurological Adverse Reactions Related to PD ‐1 Inhibitors: A Real‐World Pharmacovigilance Study. CNS Neuroscience & Therapeutics. 2026. doi:10.1002/cns.70734

BibTeX
@article{Hu2026,
  author = {Hu, Xiaofeng and Wang, Xiaoli and Tang, Bufu and Zhang, Dehuan and Cai, Rongbing and Jiang, Hui and Lin, Yaling and Song, Yiheng and Wang, Yiou and Huang, Hairuo and Guo, Dandan and Sun, Xubin and Fan, Hongjie},
  title = {Multidimensional Assessment of Neurological Adverse Reactions Related to PD ‐1 Inhibitors: A Real‐World Pharmacovigilance Study},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2026},
  doi = {10.1002/cns.70734}
}
Kostenlos starten →